Spanish pharmaceutical company PharmaMar said that clinical trials of Aplidin for the treatment of adult patients with coronavirus showed the drug’s safety and efficacy. This was stated in a press release published on the company’s website on Friday, October 16.
It is noted that in the course of the research it was possible to achieve “notable reduction of viral load and C-reactive protein in patients”.
“80.7% of patients were discharged before the 15th day of hospitalization, and 38.2% – before the eighth day (according to the protocol, they must stay in hospital for at least seven days),” – PharmaMar specified. In this regard, the company expects that soon it will be possible to begin the third phase of testing.
As it became known on October 9, the Spanish government approved the introduction of a high availability regime in the Autonomous Community of Madrid due to the spread of this infection. This measure will make it possible to limit entrance and exit from the capital and nine other settlements.
According to data from Worldometer website as of October 16, 972 958 cases of coronavirus and 33 553 lethal outcomes were registered in Spain during the whole period of epidemic.